×
Search

866-540-5505

Se Habla Espanol
Menu
Search

Our Blog

Home/Blog/Biogen to Pay $900 Million to Settle Sham Speaker Program Allegations

Biogen to Pay $900 Million to Settle Sham Speaker Program Allegations

On July 20, 2022, Biogen, Inc. (“Biogen” or the “Company”), formerly known as Biogen Idec, Inc., agreed to pay $900 million to resolve allegations that the Company violated the federal Anti-Kickback Statute (“AKS”) and False Claims Act (“FCA”) by paying physicians to prescribe its Multiple Sclerosis (“MS”) drugs. After a decade of litigation, the parties agreed to settle just one week before trial was set to begin.

The FCA allows private citizens, known as “relators” or “whistleblowers,” to bring lawsuits on behalf of the government against entities suspected of misusing government funds. These lawsuits are known as qui tam actions, derived from the Latin phrase “qui tam pro domino rege quam pro se ipso in hac parte sequitur,” meaning “one who sues in this matter for the king as well as for himself.” In 2010, Congress clarified that violations of the AKS are also FCA violations.

Importantly, because a qui tam action is filed on behalf of the government, whistleblowers must first allow the Department of Justice (“DOJ”) to investigate their claims. The government may then elect to take over prosecution of the case, do nothing and allow the relator to prosecute the case, or move to dismiss the lawsuit. If an FCA suit is successful, the relator is entitled to a share of the recovered funds.

The DOJ investigated the claims in the instant action for three years following the suit’s initiation by former Biogen employee Michael Bawduniak in 2012. The government ultimately declined to intervene in the case, permitting Bawduniak and his counsel to continue prosecuting the action independently.

Bawduniak’s allegations accuse Biogen of paying kickbacks to physicians in exchange for prescriptions of MS drugs Avonex, Tysabri, and Tecfidera (collectively, the “Drugs”). Such kickbacks violate the AKS, and under the FCA, any prescriptions resulting from AKS violations are false claims.

Bawduniak specifically alleged the kickbacks took the form of lavish meals and alcohol at “sham” speaker and consulting programs, where Biogen paid a cadre of loyal prescribers to give presentations on basic scientific information about the Drugs that was already well-known by program attendees.

In 2016, Biogen filed a motion to dismiss the lawsuit. The Company argued that its payments to physicians were pursuant to personal services contracts protected by the statutory safe harbor in the AKS, which precludes liability where “[t]he aggregate services contracted for do not exceed those which are reasonably necessary to accomplish the commercially reasonable business purpose of the service,” and the payments are “consistent with fair market value in arms-length transactions.” 42 C.F.R. § 1001.952(d)(7). Biogen also argued that Bawduniak failed to allege facts supporting the FCA’s causation element, i.e., that prescriptions for the Drugs “resulted from” the kickbacks.

In April 2018, the United States District Court for the District of Massachusetts largely denied the motion.

In its opinion, the Court identified numerous specific allegations which plausibly support the conclusion that the quantity and quality of Biogen’s speaker and consulting programs exceeded the realm of “reasonably necessary.” The Court also found for Bawduniak on the causation element, holding that “a claim is false if it seeks reimbursement for a prescription that was not provided in compliance with the Anti-Kickback Statute, regardless of whether the claim was the result of a quid-pro-quo exchange or would have been submitted even absent the kickback.”

On July 8, 2022, after many months of discovery, the Court indicated the action’s suitability for trial when it predominantly denied the parties’ motions to exclude the reports of each other’s experts. Rather than face the risk of further litigation, the parties agreed to settle the lawsuit later that month.

The settlement does not contain any admission of liability and is yet to receive final approval from the Court and the DOJ. If approved, the settlement will be among the largest ever reached in a pharmaceutical qui tam action. The caption for the lawsuit is United States ex rel. Bawduniak v. Biogen Idec, Inc., Civil Action No. 12-cv-10601-IT, filed in the United States District Court for the District of Massachusetts.

The legal team at Miller Shah LLP has significant experience representing whistleblower matters. If you have any questions regarding this subject or this post, please contact Stephen Rutkowski (strutkowski@millershah.com) or John Roberts (jcroberts@millershah.com). The firm can also be reached toll-free at (866) 540-5505.

Share Post:
facebooktwitterLinkedin

Categories

Archives

Contact
Miller Shah LLP

While this website provides general information, it does not constitute legal advice. The best way to get guidance on your specific legal issue is to contact a lawyer. To schedule a meeting with an attorney, please call 866-540-5505 or complete the intake form to email us.
Alec J. Berin - Associate

PA Philadelphia | 866-540-5505

Alexandra Kim-Lee - Project Analyst

NY New York City | 866-540-5505

Alfonso Vilaboa - Of Counsel

NJ Hoboken |

Anika S. Keuning - Project Analyst

CA San Diego | 866-540-5505

Anna D’Agostino - Associate

NY New York City | 866-540-5505

Betsy Ferling-Hitriz - Legal Assistant

CT Chester | 866-540-5505

Bruce D. Parke - Partners

PA Philadelphia | 866-540-5505

Caroline Soper - Project Analyst

NY New York City | 866-540-5505

Christopher A. Miller - Associate

PA Philadelphia | 866-540-5505

Deborah C. England - Of Counsel

CA San Francisco | 866-540-5505

Edward H. Glenn - Of Counsel

NY New York City | 866-540-5505

Edward M. Fitzgerald - Staff Attorney

CA Los Angeles | 866-540-5505

Elena M. DiBattista - Legal Assistant

FL Fort Lauderdale | 866-540-5505

Elise M. Wilson - Project Analyst

NY New York City | 866-540-5505

Eric L. Young - Of Counsel

PA Philadelphia | 866-540-5505

Finn M. Mutrux - Office Staff

CA Los Angeles | 866-540-5505

Gina S. Demetriades - Office Staff

CT Chester | 866-540-5505

Heidi A. Wendel - Of Counsel

NY New York City | 866-540-5505

Isack Fadlon - Of Counsel

CA Los Angeles |

James C. Shah - Partners

CA Los Angeles | 866-540-5505

James E. Miller - Partners

CT Chester | 866-540-5505

Jayne A. Goldstein - Partners

FL Fort Lauderdale | 866-540-5505

Jillian M. Boyce - Office Staff

CT Chester | 866-540-5505

Jocelyn McNamara - Project Analyst

NY New York City | 866-540-5505

Johanna C. Richter - Law Clerk

PA Philadelphia | 866-540-5505

John C. Roberts - Associate

PA Philadelphia | 866-540-5505

Jonathan Dilger - Office Staff

NY New York City | 866-540-5505

Julie M. Capito - Legal Assistant

CA San Francisco | 866-540-5505

Katie Edwards - Legal Assistant

PA Philadelphia | 866-540-5505

Kolin C. Tang - Partners

CA San Diego | 866-540-5505

Kyla Golding - Project Analyst

PA Philadelphia | 866-540-5505

Laurie Rubinow - Partners

CT Chester | 866-540-5505

Madison Gregg - Associate

NY New York City | 866-540-5505

Marialisa Samo - Legal Assistant

CA San Diego | 866-540-5505

Mark Xiao - Associate

NY New York City | 866-540-5505

Natalie Finkelman Bennett - Partners

PA Philadelphia | 866-540-5505

Nathan C. Zipperian - Partners

FL Fort Lauderdale | 866-540-5505

Nicholas Day - Of Counsel

NJ Hoboken | 866-540-5505

Nicholas K. Ono - Project Analyst

NY New York City | 866-540-5505

Nicole Jefferson - Project Analyst

PA Philadelphia | 866-540-5505

Raffaele Scalcione - Of Counsel

IT Milan | 866-540-5505

Robert W. Biela - Staff Attorney

PA Philadelphia | 866-540-5505

Ronald S. Kravitz - Of Counsel

CA San Francisco | 866-540-5505

Rrita Osmani - Project Analyst

CT Chester | 866-540-5505

Shuping Li - Law Clerk

NY New York City | 866-540-5505

Stephen T. Rutkowski - Law Clerk

CT Chester | 866-540-5505

Sue Moss - Legal Assistant

PA Philadelphia | 866-540-5505

Sydney D. Finlay - Associate

CA San Diego | 866-540-5505

Tina Moukoulis - Staff Attorney

PA Philadelphia | 866-540-5505

Zack P. Rozio - Of Counsel

CA Los Angeles | 310-203-0600